Publications by authors named "Emilia Rabia"
The ErbB family of receptor tyrosine kinases is a primary target for small molecules and antibodies for pancreatic cancer treatment. Nonetheless, the current treatments for this tumor are not optimal due to lack of efficacy, resistance, or toxicity. Here, using the novel BiXAb™ tetravalent format platform, we generated bispecific antibodies against EGFR, HER2, or HER3 by considering rational epitope combinations.
View Article and Find Full Text PDFChemoresistance, particularly to gemcitabine, is a major challenge in pancreatic cancer. The epidermal growth factor receptor (EGFR) and human epidermal growth factor receptors 2 and 3 (HER2, HER3) are expressed in many tumors, and they are relevant therapeutic targets due to their synergistic interaction to promote tumor aggressiveness and therapeutic resistance. Cocktails of antibodies directed against different targets are a promising strategy to overcome these processes.
View Article and Find Full Text PDFArticle Synopsis
- Preclinical and clinical studies indicate that cancer treatment with antitumor antibodies generates a specific immune response, particularly involving CD4 T cells.
- This research identifies 21 T cell epitopes derived from the human CD20 protein, which are restricted by various HLA types and can stimulate T cell activity in both healthy individuals and lymphoma patients.
- These identified CD20-derived peptides have potential as therapeutic agents to enhance or track T cell responses in patients receiving anti-CD20 treatments like rituximab.